Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells

Journal of Immunotherapy

Volumn 34, Issue 3, 2011, Pages 270-278

  Wong, Jeffrey L ^a   Mailliard, Robbie B ^a,b   Moschos, Stergios J ^a   Edington, Howard ^a   Lotze, Michael T ^a   Kirkwood, John M ^a   Kalinski, Pawel ^a,b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c University of Pittsburgh Cancer Institute ^*  (United States)

Author keywords

CTL; dendritic cells; humans; NK cells; tumor immunity; vaccination

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELANOMA ANTIGEN 1; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ANTIGEN PRESENTATION; ARTICLE; CANCER PATIENT; CANCER STAGING; CELL MIGRATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; CANCER VACCINES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL POLARITY; CHEMOKINE CCL21; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA; POLY I-C; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79953039187     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31820b370b     Document Type: Article

References (62)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252. (Pubitemid 28155090)
2. Kalinski P, Hilkens CM, Wierenga EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today. 1999;20:561-567.
3. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 2000;1:199-205.
4. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3:984-993. (Pubitemid 37521540)
5. Van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 2007;27:660-669. (Pubitemid 47615504)
6. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. (Pubitemid 34293424)
7. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045. (Pubitemid 24140436)
8. Kalinski P, Giermasz A, Nakamura Y, et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005;42:535-539. (Pubitemid 39655965)
9. Kalinski P, Moser M. Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat Rev Immunol. 2005;5:251-260. (Pubitemid 40364826)
10. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
11. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-426. (Pubitemid 47509552)
12. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity. 2008;29:319-324.
13. De Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091-5100. (Pubitemid 37413557)
14. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 1999;162: 3231-3236. (Pubitemid 29313569)
15. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
16. Kalinski P, Vieira PL, Schuitemaker JH, et al. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 hetero-dimer. Blood. 2001;97:3466-3469.
17. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64: 5934-5937. (Pubitemid 39129387)
18. Vieira PL, de Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507-4512. (Pubitemid 30238046)
19. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3: 133-146. (Pubitemid 37328691)
20. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol. 2001;2:1010-1017. (Pubitemid 33069495)
21. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193: 233-238. (Pubitemid 32524454)
22. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188: 373-386. (Pubitemid 28357765)
23. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol. 1996;26:1335-1341. (Pubitemid 26001070)
24. Nishioka Y, Hirao M, Robbins PD, et al. Induction of systemic and therapeutic antitumor immunity using intratu-moral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999;59:4035-4041. (Pubitemid 29393574)
25. Xu S, Koski GK, Faries M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003;171:2251-2261. (Pubitemid 37025530)
26. Ferlazzo G, Tsang ML, Moretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195:343-351. (Pubitemid 34461492)
27. Piccioli D, Sbrana S, Melandri E, et al. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195:335-341. (Pubitemid 34461491)
28. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195:327-333. (Pubitemid 34461490)
29. Mailliard RB, Son YI, Redlinger R, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003;171:2366-2373. (Pubitemid 37025543)
30. Agaugue S, Marcenaro E, Ferranti B, et al. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood. 2008;112:1776-1783.
31. Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5:1260-1265. (Pubitemid 41057741)
32. Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol. 2002;3:83-90. (Pubitemid 34065622)
33. Strbo N, Oizumi S, Sotosek-Tokmadzic V, et al. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity. 2003;18:381-390. (Pubitemid 36351517)
34. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003;19: 561-569. (Pubitemid 37311437)
35. Westwood JA, Kelly JM, Tanner JE, et al. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. J Immunol. 2004;172:757-761. (Pubitemid 38113730)
36. Mailliard RB, Alber SM, Shen H, et al. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med. 2005;202: 941-953.
37. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142. (Pubitemid 28018007)
38. Kapsenberg ML, Kalinski P. The concept of type 1 and type 2 antigen-presenting cells. Immunol Lett. 1999;69:5-6. (Pubitemid 29298048)
39. Chen IH, Lai YL, Wu CL, et al. Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection. Cancer Immunol Immunother. 2010;59:323-334.
40. Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58:1-14.
41. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12-17. (Pubitemid 36070411)
42. Muthuswamy R, Mueller-Berghaus J, Haberkorn U, et al. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood. 2010;116:1454-1459.
43. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid [poly(I:C)] induces stable maturation of functionally active human dendritic cells. J Immunol. 1999; 163:57-61. (Pubitemid 29295824)
44. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
45. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65: 5009-5014. (Pubitemid 40827306)
46. Ravi R, Fuchs EJ, Jain A, et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res. 2006;66:1730-1739. (Pubitemid 43259958)
47. Su Z, Kuball J, Barreiros AP, et al. Nitric oxide promotes resistance to tumor suppression by CTLs. J Immunol. 2006;176:3923-3930. (Pubitemid 44264369)
48. Basse PH, Whiteside TL, Chambers W, et al. Therapeutic activity of NK cells against tumors. Int Rev Immunol. 2001;20: 439-501. (Pubitemid 33146071)
49. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol. 2003;30:23-29. (Pubitemid 36897516)
50. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915. (Pubitemid 39273730)
51. Perrot I, Deauvieau F, Massacrier C, et al. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol. 2010;185:2080-2088.
52. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol. 2005;174:727-734. (Pubitemid 40094266)
53. Miyake T, Kumagai Y, Kato H, et al. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol. 2009;183:2522-2528.
54. Akazawa T, Ebihara T, Okuno M, et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA. 2007;104:252-257. (Pubitemid 46068018)
55. Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol. 2005;174:767-776. (Pubitemid 40094271)
56. Carson WE, Parihar R, Lindemann MJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001;31:3016-3025. (Pubitemid 32994553)
57. Parihar R, Dierksheide J, Hu Y, et al. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest. 2002;110:983-992.
58. Peritt D, Robertson S, Gri G, et al. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol. 1998; 161:5821-5824. (Pubitemid 28535946)
59. Aktas E, Akdis M, Bilgic S, et al. Different natural killer (NK) receptor expression and immunoglobulin E (IgE) regulation by NK1 and NK2 cells. Clin Exp Immunol. 2005;140:301-309. (Pubitemid 40559157)
60. Marcenaro E, Della Chiesa M, Bellora F, et al. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol. 2005;174:3992-3998. (Pubitemid 40395974)
61. Moretta A, Marcenaro E, Sivori S, et al. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 2005;26:668-675. (Pubitemid 41628200)
62. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood. 2005;106:566-571. (Pubitemid 40981252)